Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 7, 2008, Pages 745-750

  Baas, Paul ^a   Szczesna A ^b   Albert, I ^c   Milanowski, J ^d   Juhasz E ^e   Sztancsik, Z ^f   Von Pawel, J ^g   Oyama, R ^h   Burgers, S ^a  

^a Department of Thoracic Oncology ^*  (Netherlands)

^b Division III   (Poland)

^c Mátrai Allami Gyógyintézet Bronchologia   (Hungary)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^f Békés Megyei Képviselötestulet Tüdökórháza   (Hungary)

^g Asklepios Fachkliniken   (Germany)

^h DAIICHI SANKYO CO   (Japan)

Author keywords

Non small cell lung cancer; Oral drug; Second line treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; DJ 927; ETOPOSIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NAVELBINE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; ANTINEOPLASTIC AGENT; DJ927; TAXOID;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH ORGANIZATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; WEIGHT REDUCTION; DRUG ADMINISTRATION; LUNG TUMOR; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS;

EID: 50349093533     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31817c73ff     Document Type: Article

References (16)

1. Kruijtzer CM, Schellens JH, Mezger J, et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small cell lung cancer. J Clin Oncol 2002;20:4508-4516.
2. Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 2003;94:459-466.
3. Ono C, Takao A, Hayashi K, Atsumi R. DJ-927, a novel orally active taxane: 3. Preclinical pharmacokinetic studies. Proc AACR 2002;93, Abstract 3918.
4. Ono C, Minami M, Yokoyama H, et al. In vitro assessment of potential CYP-mediated drug-drug interactions of DJ-927, and cytotoxicity of its metabolites. Presented at the 17th AACR-NCI-EORTC 2005.
5. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589- 1597.
7. Broker LE, Veltkamp SA, Heath EI, et al. A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183. Clin Cancer Res 2007;13:3906-3912.
8. Pratesi G, Laccabue D, Lanzi C, et al. IDN 5390: an oral taxane candidate for protracted treatment schedules. Br J Cancer 2003;88:965- 972.
9. Vázquez S, Grande C, Amenedo M, et al. Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00). Anticancer Drugs 2004;15:489-494.
10. Buccheri G, Ferrigno D, Giordano MC. Weekly chemotherapy with cisplatin and paclitaxel in advanced NSClC: a phase II study. Monaldi Arch Chest Dis 2006;65:75-81.
11. Juan O, Albert A, Ordoño F, et al. Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study. Jpn J Clin Oncol 2002;32:449-454.
12. Berghmans T, Lafitte JJ, Lecomte J, et al. European Lung Cancer Working Party. Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party. Br J Cancer 2007; 96:1644-1649.
13. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23:8389-8395.
14. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-3157.
15. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353: 123-132.
16. Rossi D, Catalano V, Alessandroni P, et al. A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small cell lung cancer. Clin Lung Cancer 2007;8:382-385.